PD17-10 PREDICTING POSITIVE 68GA-PSMA PET/CT SCANS IN BIOCHEMICAL RECURRENCE FOLLOWING PROSTATECTOMY

You have accessJournal of UrologyProstate Cancer: Staging I (PD17)1 May 2024PD17-10 PREDICTING POSITIVE 68GA-PSMA PET/CT SCANS IN BIOCHEMICAL RECURRENCE FOLLOWING PROSTATECTOMY Maya N. Ataya, Clint D. Bahler, Michael O. Koch, Mark A. Green, Mark Tann, Ethan L. Ferguson, Heather L. Huelster, and Shayan Ahmad Maya N. AtayaMaya N. Ataya , Clint D. BahlerClint D. Bahler , Michael O. KochMichael O. Koch , Mark A. GreenMark A. Green , Mark TannMark Tann , Ethan L. FergusonEthan L. Ferguson , Heather L. HuelsterHeather L. Huelster , and Shayan AhmadShayan Ahmad View All Author Informationhttps://doi.org/10.1097/01.JU.0001010044.70939.31.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET), is a cutting-edge imaging technique that is increasingly being used in the evaluation of patients with biochemical recurrence (BCR) after definitive prostate cancer treatment. The primary aim of this study is to investigate the clinical and pathological factors that predict positive PSMA-PET scans in patients experiencing biochemical recurrence following radical prostatectomies (RP). METHODS: A retrospective review was carried out on a cohort of prostate cancer patients who underwent PSMA-PET scans at Indiana University Hospital within the period spanning from May 2017 to November 2021, identifying 400 total patients and 241 patients who had undergone PSMA-PET scans as part of their assessment for BCR post prostatectomy with no previous evidence of distant metastasis. The patients were then categorized into two groups based on the outcome of the scans: those with positive results and those with negative results. We gathered and compared clinical and pathological variables collected from patients with positive and negative PSMA-PET scans. RESULTS: Among the 241 patients identified, 151(62%) patients were identified with positive scans. Notably, cancer stage, surgical margins, and seminal vesical invasion were not found to be predictive of a positive PSMA-PET scan. PSA level at the time of the scan, ISUP, years between treatment and scan were observed to be significantly associated with predicting a positive PSMA-PET scan. In the univariate logistical regression analysis, a PSA value ≥0.2, ISUP ≥4, and ≥5 years since treatment demonstrated an odds ratio (OR) of 7.8.(p<0.001), 2.9(p=0.006), and 2.0(p=0.03) respectively. This clinically significant association remained prominent in the multivariate logistical regression with PSA value ≥0.2, ISUP ≥4, and ≥5 years since treatment demonstrating OR of 8.8(p<0.001), 4.2 (p=0.001), and 2.2(p=0.04) respectively. CONCLUSIONS: This study illustrated that among patients with biochemical recurrence post prostatectomy undergoing PSMA-PET scans a PSA value ≥0.2, ISUP ≥4, and ≥5 years since treatment were found to be clinically significant predictors of a positive PSMA-PET result. Source of Funding: Telix Pharmaceuticals and Al Christy Prostate Cancer Foundation © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e374 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Maya N. Ataya More articles by this author Clint D. Bahler More articles by this author Michael O. Koch More articles by this author Mark A. Green More articles by this author Mark Tann More articles by this author Ethan L. Ferguson More articles by this author Heather L. Huelster More articles by this author Shayan Ahmad More articles by this author Expand All Advertisement PDF downloadLoading ...